Growth Metrics

Gyre Therapeutics (GYRE) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $556000.0.

  • Gyre Therapeutics' Accounts Payables rose 8349.83% to $556000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $556000.0, marking a year-over-year increase of 8349.83%. This contributed to the annual value of $108000.0 for FY2024, which is 6957.75% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Accounts Payables of $556000.0 as of Q3 2025, which was up 8349.83% from $71000.0 recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Accounts Payables ranged from a high of $6.4 million in Q4 2021 and a low of $5000.0 during Q2 2023
  • Its 5-year average for Accounts Payables is $1.2 million, with a median of $303000.0 in 2024.
  • Per our database at Business Quant, Gyre Therapeutics' Accounts Payables plummeted by 9966.0% in 2023 and then soared by 532000.0% in 2024.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Accounts Payables stood at $6.4 million in 2021, then crashed by 98.1% to $122000.0 in 2022, then surged by 190.98% to $355000.0 in 2023, then tumbled by 69.58% to $108000.0 in 2024, then surged by 414.81% to $556000.0 in 2025.
  • Its Accounts Payables was $556000.0 in Q3 2025, compared to $71000.0 in Q2 2025 and $122000.0 in Q1 2025.